# Ipsen has acquired Sterix Limited, a UK-based company that specializes in the research and development of a new generation of steroid-based therapeutic products for use in oncology and metabolism or endocrine-related diseases. Sterix, a spin-out from the University of Bath and Imperial College, was sold to Ipsen Group, a European specialist pharmaceutical company, in 2004. Sterix specializes in the research and development of a new generation of steroid-based therapeutic products for use in oncology and metabolism or endocrine-related diseases, including cancer treatments, women''s health, diabetes and hormone-associated diseases. The acquisition allowed Ipsen to reinforce its pipeline in the field of oncology and build upon the innovative work carried out by Sterix.
